Oxford Nanopore Technologies aims to make molecular analysis accessible to anyone, anywhere. Our nanopore-based technology provides fast, affordable, and information-rich analysis of DNA, RNA, and other molecules. It can read the genetic code of people, bacteria,...

We are honoured to share that InGeNA is a nominee for the Health Industry Hub Catalysts for Change Awards 2025 in the Excellence in Collaboration category. This recognition reflects our ongoing commitment to advancing genomics in Australia through genuine...

InGeNA is thrilled formalise our partnership with Inherited Cancers Australia. After a long relationship with ICA CEO Sarah Powell through our Consumer Advisory Group, we're excited to be entering an official partnership. Inherited Cancers Australia is the only...

InGeNA warmly welcomes our new member, Twist Bioscience. Twist Bioscience works in service of people who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and academic research, their unique silicon-based DNA...

InGeNA warmly welcomes our new member, Rhythm Biosciences. Rhythm Biosciences (ASX:RHY) is transforming cancer diagnostics through innovative technologies that predict, detect, characterise, and support early intervention. Their flagship blood-based technology...

InGeNA is delighted to announce our new partnership with ARCS Australia. This collaboration brings together the complementary strengths of both organisations — ARCS as the professional development association for the therapeutics industry, and InGeNA as the peak body...

Pathology Technology Australia and the Industry Genomics Network Alliance (InGeNA) warmly welcome the formal establishment of Genomics Australia as a national body under the Department of Health and Aged Care from 1 July. The creation of Genomics Australia marks a...

On 1 July 2025, the Australian Government officially launched Genomics Australia, a national agency established to lead the integration of genomics into Australia’s healthcare system. The initiative represents a significant policy and structural shift, designed to...

InGeNA warmly welcomes our new member, Oncoparse. Oncoparse is an early-stage genomics company developing next generation diagnostics to address critical blind spots in pancreatic cancer care. Our mission is to transform pancreatic cancer into a manageable condition...

InGeNA's mission includes supporting and driving equitable access to genomics across all Australian communities. We are delighted to support the Australian Alliance for Indigenous Genomics: ALIGN, and are proud sponsors for the SING 2025 program. The ALIGN Victoria...

InGeNA warmly welcomes our new member, 360biolabs. 360biolabs is Australia’s most comprehensive bioanalytical laboratory providing a single laboratory for all of your clinical trial requirements. We support pharmacokinetic (PK) analysis (large molecule, small...

InGeNA welcomes GenIMPACT as our newest member.  Read more about GenIMPACT below, and on their website: GenIMPACT: Centre for Economic Impacts of Genomic Medicine at Macquarie University undertakes cutting-edge research into the economic impacts and cost-effectiveness...

InGeNA welcomes QIAGEN as our newest member.  Read more about QIAGEN below, and on their website: QIAGEN pushes the boundaries of innovation to improve our understanding of DNA, RNA and proteins – the building blocks of life. We enable our customers to unlock valuable...

InGeNA welcomes QUT's Centre for Genomics & Personalised Health as our newest associate member.  Read more about QUT CGPH below and on their website: The QUT Centre for Genomics and Personalised Health aims to improve human health by discovering better methods of...

Rare Disease Day, observed annually on the last day of February, is a global initiative to raise awareness of rare diseases and the challenges faced by those living with them. For the 300+ million people worldwide living with rare diseases (many of which have a...

InGeNA warmly welcomes our new Member-Elected Board Director – Oliver Bonaccorso Oliver brings 17 years of experience in the genomics industry, having held commercial and strategic roles across the life sciences, diagnostics and pharmaceutical sectors. As the Johnson...

InGeNA warmly welcomes our new Member-Elected Board Director – Jessica Poy Jessica brings over 15 years of commercial leadership experience, with the last five years dedicated to genomics, life sciences, and research-industry partnerships. As the Chief Commercial...

InGeNA would like to give a heartfelt welcome to our new Independent Director – Edith Hurt. Edith brings more than 10 years of commercial and not-for-profit Non-Executive Director experience in health, community and business sectors. She was the inaugural Company...

InGeNA is delighted to announce the appointment of Carl Stubbings as our new Chair. With an exceptional career spanning leadership roles in biotechnology and genomics, Carl brings extensive strategic insight to our organisation. Recently stepping down from his role as...

InGeNA welcomes INSiGENe as our newest member.  Read more about INSiGENe here and on their website: INSiGENe delivers expert bioinformatics, biostatistics, and data science services to accelerate breakthroughs in life sciences. Their agile team of experts provides...

We extend our thanks and best wishes to Kathy Campbell as she steps down as InGeNA Chair. Kathy's steadfast leadership, advocacy, and support have been pivotal in shaping InGeNA's journey to incorporation and beyond.   Over the past two years, Kathy has led InGeNA...

InGeNA is pleased to welcome the announcement of Genomics Australia, a significant step forward in advancing the integration of genomics into the Australian healthcare system. This initiative lays the foundation for improving health outcomes through the application of...

AWS empowers healthcare and life sciences organizations with innovative technologies that deliver scalable, secure, and cost-effective solutions to accelerate genomic discoveries. From migrating and securely storing genomic data, to facilitating secondary and tertiary...

The Industry Genomics Network Alliance (InGeNA) is Australia’s peak body for genomics and personalised healthcare, bringing together industry leaders across diagnostics, therapeutics, software, data, and analytics. Our members range from large multinationals to...

AGRF (Australian Genome Research Facility) is Australia’s largest genomics facility offering a comprehensive suite of 'omics' services, delivered through our national network of NATA accredited laboratories.    We work in partnership with clients across academia,...

InGeNA welcomes Bioplatforms Australia as a new member.  Read more about Bioplatforms Australia here and on their website: Bioplatforms Australia is a non-profit organisation that supports Australian Life science research by investing in state-of-the-art...

InGeNA and Pathology Technology Australia welcomes the Federal Government’s announcement of a ban on genetic discrimination in life insurance. This is an important step toward removing barriers that have long prevented Australians from fully benefiting from genomic...

InGeNA welcomes Tektology as a new member.  Read more about Tektology here and on their website: Tektology is an international health innovation & strategy consultancy headquartered in the UK and with offices in Australia, Saudi Arabia, and India. We are senior...

InGeNA welcomes Gene S as a new member.  Read more about Gene S here and on their website: Gene S is a Western Australian company with a groundbreaking pharmacogenomic technology platform. Gene S’s PGx solution, featuring advanced genetic testing and reporting...

InGeNA welcomes Genomical® as a new member.  Read more about Genomical® here and on their website: New venture to support Genomical® in the sustainability and scale-up of clinical genomic testing Transcendomics is a new spinout company from the Melbourne Genomics...

The InGeNA Board is thrilled to announce Erin Evans as the incoming CEO, beginning her tenure in July 2024. Erin brings a wealth of experience and a track record of success, having served as CEO of Life Sciences Qld, where she spearheaded transformative initiatives...

InGeNA welcomes MGI as a new member.  Read more about MGI here and on their website: MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through...

InGeNA welcomes SydPath Pathology as a new member.  Read about the great work that SydPath does here and on their website: SydPath provides purpose driven, personalised pathology with an unwavering commitment to delivering high quality tests with a fast time to...

Our purpose Making personalised healthcare accessible to all Australians by harnessing the collective skills and expertise of industry to accelerate the adoption of genomics Our principles Equity We have a strong commitment to equity of access to genomics for all...

InGeNA proudly supports the Summer Internship for Indigenous Genomics (SING) SING Australia - SING - Summer Internship for Indigenous Peoples in Genomics We received this email following our support of the 2023 event: Thank you very much for your support. The InGeNA...

InGeNA advocates for a legislative ban on using genetic-testing results in life insurance underwriting, arguing it ensures people can undergo genetic testing without fear of discrimination. InGeNA emphasises the ban should have no exemptions for clear consumer and...

InGeNA members will take part in a strategic planning day on May 23 to refresh the current strategy, agree key areas of focus and discuss potential future directions of the organisation to best serve the interests of the Australian genomics community. Chair Kathy...

InGeNA’s vision of realising the full potential of genomics to personalise healthcare cannot be achieved without national and jurisdictional level strategies and initiatives from governments. Launching today on our website we have collated and summarised genomics...

Australian Genomics has completed the full report for the NAGIM Implementation Recommendations and delivered it to the Australian Department of Health. An important part of the report is the recognition that "engaging with industry to contribute to health genomics...

As we start the new year, InGeNA continues our mission to realise the full potential of genomics to personalise healthcare. This year we look forward to working closely with our partners to advocate for the benefits genomics can bring to both patient outcomes and...